RBC Capital raised the firm’s price target on NewAmsterdam Pharma (NAMS) to $47 from $44 and keeps an Outperform rating on the shares. The firm updated models for several biotech companies after meeting with managements.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAMS:
- 3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts
- NewAmsterdam Pharma: PREVAIL Parallels, Robust Trial Execution, and 2026 Milestones Support Buy Rating
- NewAmsterdam Pharma: Obicetrapib Momentum, 2026 Inflection Catalysts, and Undervalued Blockbuster Potential Support Buy Rating
- NewAmsterdam Pharma: Late-Stage Obicetrapib Momentum, Regulatory Catalysts, and Strong Cash Position Underpin Buy Rating
- NewAmsterdam Pharma outlines 2026 goals after strong 2025 progress